Company News

Cancer vaccine firm Oxford Vacmedix confirms appointment of new Directors

Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-­‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series […]

Cancer vaccine firm Oxford Vacmedix confirms appointment of new Directors Read More »

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research Organisation

Oxford Vacmedix appoints Shanghai based PharmaLegacy to carry out the proof of concept work of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that PharmaLegacy of Shanghai, China has been appointed to complete the proof

Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research Organisation Read More »